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Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of tuber-
culosis (TB), continues to cause considerable global morbidity 
and mortality, with approximately 9.6 million new cases and 1.5 
million deaths in 2014 (1, 2). Resurgence of TB is also the num-
ber-one cause of death in HIV-infected individuals, particularly in 
endemic areas of sub-Saharan Africa (1, 3). This catastrophic situ-
ation is in part due to the low efficiency of the only licensed anti-
TB vaccine, bacillus Calmette–Guérin (BCG), in affording protec-
tion against pulmonary TB and preventing disease transmission 
(1). Despite the availability of effective TB drugs, poor adherence 
to long treatment regimens of at least 6 months not only worsens 
the situation for the individual patient but also contributes to the 
emergence of drug-resistant Mtb strains.
Upon inhalation, Mtb bacilli are taken up by, and are capable 
of persisting within, myeloid cell populations in the lung over pro-
longed periods of time, and sterile eradication is rarely achieved. 
An estimated one-third of the world’s population is latently infected 
with Mtb without showing signs of active TB disease (4). Mtb uses a 
variety of sophisticated effector molecules that can interfere with a 
multitude of cellular functions including pattern recognition, anti-
gen presentation, and phagolysosome formation, thereby quickly 
establishing an intracellular survival niche, where it hides from the 
host’s innate and adaptive immune response (5, 6). The use of such 
pathogenic decoy and evasion mechanisms not only contributes to 
the success of Mtb but also provides significant challenges for the 
development of effective new intervention measures (6).
Containment of Mtb infection requires functional CD4+ T cell 
responses (7), in particular the production of IFN-γ and the forma-
tion of granulomatous lesions (8). In the absence of CD4+ T cells, 
IFN-γ, its receptor, or downstream effector molecules such as induc-
ible NOS (iNOS), susceptibility and disease are exacerbated (9–11). 
Accordingly, coinfection with HIV, which impairs CD4+ T cells dur-
ing its reproduction, is one of the major factors contributing to the 
spread of TB (12). Impairment of CD4+ T cells compromises the 
integrity of TB lung granulomas, eliminates a major source of IFN-γ, 
and affects the main target of many TB vaccine candidates. Cognate 
activation and expansion of Mtb-specific conventional CD4+ T cells 
of the Th1 and Th17 lineages through the use of immunodominant 
antigens, such as Ag85 cognates, is the main strategy in current TB 
vaccine development (3). However, the recent failures of the most 
advanced TB vaccine candidate, MVA85A, in 2 clinical trials (13, 
14), as well as the failure of new TB drug treatment regimens (15), 
highlight an urgent need to reconsider the design of TB interven-
tion. Furthermore, the evolutionary conservation of Mtb epitopes for 
human T cells among many mycobacterial species supports the idea 
that human T cells predominantly recognize broadly shared myco-
bacterial antigens (16) and that Mtb can even benefit from cognate T 
cell recognition (17). Therefore, it is highly desirable to have a more 
detailed understanding of how different immune cell populations, 
such as unconventional T cells, γδ T cells, mucosal-associated invari-
ant T (MAIT) cells, invariant NK T (iNKT) cells, CD1-restricted T 
cells, as well as NK cells and even Ab-producing cells, are activated 
and participate in a protective immune response against Mtb (1).
IFN-γ is a critical mediator of host defense against Mycobacterium tuberculosis (Mtb) infection. Antigen-specific CD4+ T cells 
have long been regarded as the main producer of IFN-γ in tuberculosis (TB), and CD4+ T cell immunity is the main target of 
current TB vaccine candidates. However, given the recent failures of such a TB vaccine candidate in clinical trials, strategies 
to harness CD4-independent mechanisms of protection should be included in future vaccine design. Here, we have reported 
that noncognate IFN-γ production by Mtb antigen–independent memory CD8+ T cells and NK cells is protective during Mtb 
infection and evaluated the mechanistic regulation of IFN-γ production by these cells in vivo. Transfer of arenavirus- or 
protein-specific CD8+ T cells or NK cells reduced the mortality and morbidity rates of mice highly susceptible to TB in an IFN-γ–
dependent manner. Secretion of IFN-γ by these cell populations required IL-18, sensing of mycobacterial viability, Mtb protein 
6-kDa early secretory antigenic target–mediated (ESAT-6–mediated) cytosolic contact, and activation of NLR family pyrin 
domain–containing protein 3 (NLRP3) inflammasomes in CD11c+ cell subsets. Neutralization of IL-18 abrogated protection in 
susceptible recipient mice that had received noncognate cells. Moreover, improved Mycobacterium bovis bacillus Calmette-
Guérin (BCG) vaccine–induced protection was lost in the absence of ESAT-6–dependent cytosolic contact. Our findings provide 
a comprehensive mechanistic framework for antigen-independent IFN-γ secretion in response to Mtb with critical implications 
for future intervention strategies against TB.
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ficity for either the SIINFEKL epitope of the OVA protein (OT-ITg) or 
the KAVYNFATC epitope of the LCM virus (P14Tg), respectively (36, 
37). Transfer of either OT-ITg or P14Tg memory CD8+ T cells more 
than doubled the mean survival time for Rag2–/– Il2rg–/– mice (Fig-
ure 1A). In contrast, treatment with anti–IFN-γ Ab after transfer of 
OT-ITg cells into Rag2–/– Il2rg–/– mice (Figure 1A) or transfer of OT-ITg 
cells into Ifngr–/– mice did not prolong survival (Figure 1B), indicating 
that host protection by noncognate memory CD8+ T cells involves 
downstream effects of IFN-γ. Similarly, when in vitro–expanded 
purified NK cells were transferred into Rag2–/– Il2rg–/– mice, survival 
time was substantially prolonged and reverted almost to the survival 
time of Rag1–/– mice, which naturally contain NK cells (Figure 1A). In 
contrast, the transfer of Ifng–/– NK cells did not prolong the survival 
of Rag2–/– Il2rg–/– mice (Figure 1A). These results demonstrate an 
inherent capacity of Mtb-unrelated virus– and OVA-specific memory 
CD8+ T cells as well as NK cells to mediate early IFN-γ–dependent 
control of TB in the absence of other lymphocytes.
To address whether noncognate cells also improved the control 
of Mtb infection in immunocompetent hosts, we additionally trans-
ferred OT-ITg cells into B6 (CD45.1+) mice (Figure 1, C and D and 
Supplemental Figure 1). Four weeks later, when OT-ITg cells had con-
verted into central memory T cells, the mice were aerosol infected 
with Mtb. Consistent with previous findings, immunocompetent B6 
mice were resistant to Mtb and only succumbed to the infection after 
200 to 300 days (Figure 1A). To exclude the effects of endogenous T 
cell responses, we focused on early time points measuring bacterial 
loads in lung and spleen 7 and 14 days post infection (p.i.). At both 
time points, the transfer of OT-ITg cells significantly reduced bac-
terial numbers in the lung (Figure 1E) and slowed the progression 
of Mtb to the spleen (Figure 1F). Whereas 7 of 9 control mice had 
Mtb in the spleen 14 days p.i., only 3 of 11 mice that received OT-ITg 
cells did. Collectively, these results demonstrate that Mtb-unrelated 
memory CD8+ T cells improve early protection against Mtb, not only 
in immunocompromised but also in immunocompetent hosts.
Innate IFN-γ secretion in response to Mtb requires bacterial via-
bility and IL-18. Next, we addressed the mechanistic requirements 
of how Mtb-unrelated memory CD8+ T cells and NK cells secrete 
IFN-γ in response to Mtb. Noncognate production of IFN-γ in 
response to other pathogens such as Salmonella enterica serovar 
typhimurium (Stm), Pseudomonas aeroginosa, and L. monocytogenes 
has been linked to the upstream effects of IL-18 (21–23). To interro-
gate whether and how early IFN-γ secretion in response to myco-
bacteria requires IL-18, we established a short-term in vivo expo-
sure model, in which naive B6 mice were exposed to either live or 
dead mycobacteria for a maximum of 48 hours. At 2, 18, 24, and 48 
hours after exposure, IFN-γ secretion by CD3+CD4+, CD3+CD8+, 
CD3+CD4–CD8– (double-negative [DN]), and CD3–NK1.1+ cells in 
lung, spleen, and lymph nodes (LNs) was assessed directly ex vivo. 
Because antigen-specific T cell responses take at least 3 to 4 days to 
develop (38), any IFN-γ secretion observed within a 48-hour time 
frame in Mtb-naive mice must be unrelated to Mtb.
In contrast to Stm, which induces IFN-γ secretion by non-CD4 
immune cells within 2 hours (ref. 21 and Figure 2A), neither live or 
inactivated BCG nor Mtb was able to induce IFN-γ secretion within 
2 hours after i.v. injection (Figure 2A and Supplemental Figure 2, 
A and B). BCG, heat-killed BCG (HKBCG), and irradiated Mtb 
H37Rv (iMtb) did not induce any IFN-γ over a 48-hour period (Sup-
In contrast to cognate T cell receptor/MHC–mediated (TCR/
MHC-mediated) priming of antigen-specific IFN-γ secretion by 
conventional CD4+ and CD8+ T cells (18), IFN-γ secretion can also 
be antigen independent and driven by cytokines, including IL-18 
(19, 20). Initially thought to only be produced by NK cells and γδ 
T cells, IL-18–driven IFN-γ production was recently expanded to 
include memory CD8+ T cells as IFN-γ producers as well (21–25). 
Secretion of bioactive IL-18 requires proteolytic cleavage from its 
biologically inactive precursor pro–IL-18 through caspase-1 (26), 
which in turn depends on the upstream assembly and activation 
of inflammasomes through the engagement of cytosolic pattern 
recognition receptors (PRRs) (26). Intriguingly, not only have defi-
ciencies in caspase-1 and IL-18 (27, 28) been implicated in impaired 
immunity to Mtb, but a deficiency in a PRR that is required for the 
upstream activation of caspase-1 has been implicated as well (29). 
These results point to an important host-protective role for the 
caspase-1/IL-18/IFN-γ axis and suggest that strategies aimed at 
targeting cytosolic PRRs beyond adjuvant immunotherapy (30) 
could serve as a means of inducing IL-18–mediated IFN-γ produc-
tion to control Mtb infections.
Consistent with this hypothesis, it was recently demonstrated 
in a model of experimental Listeria monocytogenes infection that 
rapid, cytokine-driven IFN-γ secretion by memory CD8+ T cells 
significantly orchestrates host innate immune responses and has 
an impact on the magnitude of the recall response after vaccina-
tion (31). Vaccination strategies that are independent from specific 
TCR-MHC interactions could therefore be an attractive target 
to induce host-protective IFN-γ production as well as a means to 
overcome Mtb-induced MHC downregulation and the reliance on 
mostly unknown Mtb-nonspecific MHC antigens (16) that might 
even benefit the pathogen rather than the host (17). Therefore, 
using an established murine model of TB, our study aimed to inves-
tigate whether Mtb-independent immune responses contribute to 
immunity against Mtb and, if so, to dissect their mechanistic regu-
lation in vivo as well as to elucidate potential applications for vac-
cine improvement and host-directed therapeutic approaches.
Results
Noncognate cell sources of IFN-γ are sufficient to mediate early control 
of Mtb infection. We harnessed an experimental TB model in mice to 
determine whether memory CD8+ T cells and NK cells unrelated to 
Mtb can mediate protection against TB. Whereas WT C57BL/6 (B6) 
mice are relatively resistant to a low-dose aerosol infection with 
Mtb H37Rv (Figure 1A), mice that lack IFN-γ, the IFN-γ receptor, or 
all lymphocytes (Rag2–/– Il2rg–/–) rapidly succumb to low-dose Mtb 
infection within approximately 30 days (refs. 11, 32, 33, and Figure 
1A). Given that noncognate immune cells can provide protection 
against Mtb in the absence of other lymphocytes, adoptive transfer 
of mycobacteria-independent memory CD8+ T cells or selected NK 
cells should significantly prolong the survival of Rag2–/– Il2rg–/– mice.
To investigate this hypothesis, we generated both OVA- and 
lymphocytic choriomeningitis virus–specific (LCMV-specific) MHC 
class I–restricted effector CD8+ T cells (34, 35) and then purified and 
adoptively transferred them into naive Rag2–/– Il2rg–/– mice (Supple-
mental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI84978DS1). In this model system, within 
weeks, these T cells convert into central memory T cells with speci-
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plemental Figure 2E). Of note, the strength of the IFN-γ response 
correlated with the amount of viable bacteria in the respective tis-
sue (Figure 2F), starting with a minimal number of 1,000 CFU in 
the organ 24 hours p.i. (dotted line, Figure 2F) to obtain a reliable 
IFN-γ response (~2% LN s.c.; dotted line Figure 2E). Given the often 
reduced number of recoverable bacteria relative to the infectious 
dose, these results could explain why an aerosol infection with 
1,000 CFU Mtb H37Rv did not induce a detectable IFN-γ response 
in this model (Supplemental Figure 2F). Collectively, these results 
support the requirement for a spatially distinct pattern of pathogen 
recognition (22) and suggest that the presence of high numbers of 
live bacteria within the tissue is a crucial requirement for rapid, non-
cognate IFN-γ production. We conclude that innate IFN-γ secretion 
in response to Mtb depends on the sensing of viable bacteria and is 
driven by the secretion of IL-18. Given the ubiquitous distribution 
and magnitude of IFN-γ secretion by CD3–NK1.1+ and CD3+CD8+ 
cells 24 hours after i.v. Mtb injection, we subsequently focused on 
these cell types and the timing following an i.v. infection route for 
further dissection of the underlying mechanistic requirements.
Innate IFN-γ depends on RD1 and ESAT-6–mediated cytosolic 
contact. Live BCG did not lead to an IFN-γ response, suggesting 
that Mtb virulence factors play a critical role. To identify the under-
lying mechanisms, we further probed the bacterial factors that 
drive early, IL-18–dependent IFN-γ secretion by exposing naive 
B6 mice to a panel of recombinant bacterial strains or Mtb com-
ponents for 24 hours.
plemental Figure 2A). In contrast, significant production of IFN-γ 
in response to live Mtb H37Rv was detected at 18 hours and peaked 
at approximately 24 hours after i.v. injection (Figure 2B). Approxi-
mately 40% of NK cells (30% in the lung), 8% of DN T cells (4%–
5% in the lung), and 2% of CD8+ T cells in the spleen secreted IFN-γ 
24 hours after systemic Mtb exposure (Figure 2B and Supplemen-
tal Figure 2B). Further phenotypic characterization of IFN-γ–pro-
ducing DN T cells revealed an equal ratio of αβ TCR+ and γδ TCR+ 
cells (Supplemental Figure 2C). All IFN-γ–producing CD8+ T cells 
stained positive for CD44 and CD62L and displayed a diverse TCR 
Vβ chain usage (Supplemental Figure 2C). These results identify 
IFN-γ–producing CD8+ T cells as multispecific central memory T 
cells (39), making it unlikely that these T cells possess an alterna-
tive TCR specific for Mtb, as has been suggested for CD4+ Tg T cells 
(40). In line with these findings, transferred OT-ITg cells displayed 
a central memory phenotype 4 weeks after adoptive transfer and 
secreted IFN-γ 24 hours after Mtb challenge (Supplemental Figure 
2D), confirming that the response was noncognate. Importantly, 
serum IL-18 concentrations correlated with the strength of IFN-γ 
production, and IL-18 was detected only after injection of live Mtb 
but not live BCG or iMtb (Figure 2C and Supplemental Figure 2E).
In contrast to i.v. injection, which induced a strong, dose-de-
pendent systemic IFN-γ response (Figure 2D), Mtb administration 
via the intradermal (i.d.), subcutaneous (s.c.), or intratracheal (i.t.) 
infection route induced only local, tissue-restricted IFN-γ secre-
tion and significantly lower secretion of IL-18 (Figure 2E and Sup-
Figure 1. Noncognate memory CD8+ T cells and NK cells are sufficient to mediate early IFN-γ–dependent control of Mtb infection. (A–F) Naive B6, 
Ifngr–/–, Rag1–/–, Rag2–/– Il2rg–/– mice, as well as Rag2–/– Il2rg–/– (A), Ifngr–/– (B), and B6 (C–F) mice that had received either OT-ITg cells (A–E), P14Tg cells 
(A), NK cells, or Ifng–/– NK cells (A) were infected with 200 CFU Mtb H37Rv via the aerosol route, and survival (A and B), OT-ITg cell numbers among CD8+ T 
cells (C and D), and CFU (E and F) were assessed over time. For neutralization of IFN-γ (A), mice received weekly i.p. injections of 200 μg anti–IFN-γ mAb. 
Results are presented as individual data points (D–F), pooled data means (A and B), or representative FACS plots (C) of 7 to 22 (A), 7 (B), and 8 to 11 (C–F) 
mice per group from 2 (B–F) or 5 (A) pooled, independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001, by log-rank (Mantel-Cox) test (A and B) or 
unpaired, 2-tailed Student’s t test per time point (E and F).
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were unable to induce phagosomal rupture and establish cyto-
solic contact (47). Overall, these results suggest that a functional 
RD1 locus and ESAT-6–mediated cytosolic contact are required to 
induce IL-18–dependent IFN-γ secretion in response to Mtb in vivo.
Innate IFN-γ depends on canonical NLRP3 signaling. We next set 
out to determine the host signaling pathways required for innate 
IFN-γ production. To this end, we took advantage of a panel of 
genetically modified mouse strains that received Mtb H37Rv i.v.
The absence of rapid IFN-γ production in Il18–/– mice con-
firmed our previous results demonstrating a direct correlation 
between IL-18 secretion and IFN-γ secretion (Figure 4, A–C, and 
Supplemental Figure 4, A and B). Since secretion of bioactive IL-18 
depends on the enzymatic cleavage of pro–IL-18 by caspase-1 (26), 
we tested caspase-1–/– mice and found that they failed to secrete 
IL-18 and IFN-γ (Figure 4, A–C, and Supplemental Figure 4, A and 
B). Activation of caspase-1 involves the sensing of danger molecules 
or stress signals via upstream cytosolic PRRs, so-called inflam-
masomes (26), and this process can be enhanced and controlled 
via TIR domain–containing adaptor-inducing IFN-β (TRIF-depen-
dent) caspase-11 activation (48). Although caspase-1 and -11 dou-
ble-KO mice failed to respond to Mtb challenge, the response in 
caspase-11–/– single-KO mice was indistinguishable from that in B6 
controls, indicating a requirement for caspase-1–mediated cleav-
age and excluding noncanonical caspase-11 involvement (Figure 
Consistent with our previous results, neither purified Mtb com-
ponents, including the cell wall, cell membrane, whole-cell lysates, 
cytosolic components, and DNA, nor BCG induced IL-18 or IFN-γ 
secretion (Figure 3, A, B, D, E, G, and H, and Supplemental Figure 
3, A, B, D, and E). Moreover an Mtb Δ region of difference 1 (ΔRD1) 
mutant (41) that lacks the RD1, encoding parts of the ESX-1 type VII 
secretion system that is absent from all BCG strains (41, 42), failed to 
induce rapid IL-18–dependent IFN-γ secretion (Figure 3, C, F, and I, 
and Supplemental Figure 3, C and F). In contrast, when a BCG strain 
reconstituted with the extended RD1 locus from Mtb (BCG::RD1) 
(43) was used, production of both IL-18 and IFN-γ was restored (Fig-
ure 3, C, F, and I, and Supplemental Figure 3, C and F–H), pointing 
to a crucial role of the RD1-encoded ESX-1 secretion system. Using 
a panel of recombinant BCG::RD1 and Mtb strains, we identified the 
esxA gene within the RD1 locus as indispensable for production of 
both IL-18 and IFN-γ (Figure 3, C, F, and I, and Supplemental Figure 
3, C and F). The esxA gene encodes for the 6-kDa early secretory 
antigenic target (ESAT-6), a prominent immunogen and virulence 
factor of Mtb (44, 45). Neither Mtb ΔESAT-6 (46) nor a recombi-
nant BCG::RD1 strain secreting C-terminal–truncated ESAT-6 
(BCG::RD1 ESAT-6 Δ92-95) induced production of IL-18 or IFN-γ 
(Figure 3, C, F, and I, and Supplemental Figure 3, C and F). These 
results relate to previous work, in which tubercle bacilli that did 
not produce ESAT-6 or that lacked the C-terminal end of ESAT-6 
Figure 2. Innate IFN-γ secretion depends on IL-18 and requires Mtb viability. (A) Percentage of IFN-γ+ cells among total viable splenic CD3+CD8+, 
CD3+CD4+, CD3+CD4–CD8– (DN) T cells and CD3–NK1.1+ cells 2 hours after B6 mice were injected with 1 × 108 CFU of either Stm (as a positive control), BCG, 
HKBCG, Mtb H37Rv, iMtb, or PBS. (B) Percentage of IFN-γ+ cells among total viable splenic CD3+CD8+, CD3+CD4+, CD3+CD4–CD8– (DN) T cells and CD3–NK1.1+ 
cells at different time points after B6 mice were injected with 1 × 108 CFU Mtb H37Rv. (C) Serum IL-18 concentrations at different time points after injection 
of B6 mice with 1 × 108 CFU Stm, BCG, Mtb H37Rv, or iMtb H37Rv. (D) Percentage of IFN-γ+ cells among total viable CD3–NK1.1+ in spleen and lung 24 hours 
after injection of different doses of Mtb H37Rv, BCG, or iMtb H37Rv. (E and F) Percentage of IFN-γ+ CD3–NK1.1+ cells (E) and recoverable CFU (F) from either 
spleen, lung, or draining LN 24 hours after injection of 1 × 108 CFU Mtb H37Rv via the i.v., i.d., i.t., or s.c. route. Results are presented as pooled data (mean 
± SEM) (A–F) and representative FACS plots (E) of 5 to 9 (A), 5 to 10 (B and C), 5 (D), or 7 to 10 (E and F) mice per group from at least 2 to 3 pooled, indepen-
dent experiments. Dotted lines indicate the mean percentage of the smallest reliably detectable IFN-γ+ response by CD3–NK1.1+ cells (E) and the respective 
mean recoverable CFU (F) 24 hours after Mtb exposure.
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observed in Ifngr–/– mice (Figure 4, D–F). This might be due to a 
positive feedback loop for IFN-γ that has been reported previously 
for the secretion of IL-1β (52) or to a lower induction of NK cell–
recruiting chemokines in the absence of IFN-γ signaling (53, 54).
Taken together, these results indicate that rapid, noncognate 
IFN-γ secretion in vivo in response to Mtb depends on the NLRP3/
caspase-1/IL-18 axis. Although ESAT-6 has been shown to be both 
necessary and sufficient to activate the NLRP3 inflammasome in 
vitro (55), the underlying mechanisms remain unclear. Given the 
membrane-damaging features of ESAT-6 (41, 56), the suggested 
perturbation of host cell membranes to induce a potassium efflux 
(55) provides a possible explanation. However, in our system, 
cytosolic NLRP3 activation appears to at least be independent of 
P2X7 receptor–dependent potassium efflux, since P2x7r–/– mice 
secreted both IL-18 and IFN-γ in response to Mtb (Figure 4, D–F, 
and Supplemental Figure 4, C and D).
DCs are required for IL-18 secretion. In order to potentially tar-
get ESAT-6–dependent NLRP3 activation for preventive or thera-
peutic intervention strategies, it would be desirable to identify the 
Mtb-sensing and IL-18–secreting cell type in vivo.
Thus, to determine whether IL-18 needs to be secreted by a 
hematopoietic or nonhematopoietic cell type, we generated BM 
chimeras and analyzed IFN-γ secretion in spleen and lung as well 
4, A–C, and Supplemental Figure 4, A and B). Accordingly, NLR 
family pyrin domain–containing protein 3 (NLRP3) and apoptosis- 
associated speck-like protein containing a carboxy terminal CARD 
(ASC), molecules involved in canonical activation of caspase-1 (26), 
were crucial, since secretion of both IL-18 and IFN-γ was impaired 
in Nlrp3–/– and Asc–/– mice (Figure 4, A–C, and Supplemental Figure 
4, A and B). To determine the involvement of cytosolic DNA recog-
nition, which has been suggested to be a host defense mechanism 
against Mtb (29, 49–51), we also tested mice lacking the cytosolic 
DNA sensors stimulator of IFN genes (STING) and absent in mel-
anoma 2 (AIM2). Both, Sting–/– and Aim2–/– mice secreted levels of 
IL-18 and IFN-γ that were comparable to those in control animals, 
excluding a role for cytosolic DNA sensing (Figure 4, A–C, and Sup-
plemental Figure 4, A and B). Furthermore, the response did not 
require IL-1β (Il1b–/–) or TLR2/4 (Tlr2–/–/Tlr4–/–), was independent 
of upstream type I IFN signaling (Ifnabr–/–), and did not depend 
on IL-15 (23) (Figure 4, A–H, and Supplemental Figure 4, A–F). 
However, IFN-γ secretion depended on IL-18 receptor signaling, 
because IFN-γ production, but not IL-18 secretion, was impaired 
in Myd88–/– mice (Figure 4, A–C, and Supplemental Figure 4, A 
and B), indicating that MyD88 signaling must occur downstream 
of the IL-18 receptor, but not downstream of TLRs. A slight reduc-
tion in secretion of both IL-18 and IFN-γ by NK cells in the lung was 
Figure 3. Innate IFN-γ depends 
on RD1 and ESAT-6–mediated 
cytosolic contact. (A–F) Percentage 
of IFN-γ+ cells among total viable 
CD3–NK1.1+ (A–C) and CD3+CD8+ 
(D–F) lung cells and serum IL-18 
concentrations (G–I) 24 hours after 
B6 mice were injected with different 
purified mycobacterial ligands (A, D, 
and G) or 1 × 108 CFU WT or recom-
binant Mtb or BCG strains (B, C, E, F, 
H, and I). Individual data points of 
3 to 15 mice per group from at least 
2 pooled, independent experiments 
are shown. *P < 0.05, **P < 0.01, 
and ***P < 0.001, by 1-way ANOVA. 
rESAT-6, recombinant ESAT-6.
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as IL-18 levels in serum 24 hours after challenge with Mtb H37Rv. 
Recipient mice reconstituted with Il18–/– BM secreted significantly 
less IL-18 and IFN-γ compared with that observed in mice recon-
stituted with WT BM (Figure 5, A, B, and G, and Supplemental 
Figure 5, A and B), showing that a BM-derived cell type produces 
IL-18. CD11c+ cells have been suggested to rapidly produce IL-18 
upon pathogen encounter (21). To determine whether CD11c+ cells 
are required for rapid IL-18 secretion in response to Mtb, we gener-
ated straight and mixed BM chimeras using the CD11cDTR mouse 
model, which allows for specific depletion of CD11c+ cells with 
diphtheria toxin (DTX) (Supplemental Figure 5, G and H). When 
CD11cDTR chimeras were treated with DTX, secretion of both 
IL-18 and IFN-γ was significantly reduced (Figure 5, C and D, and 
Supplemental Figure 5, C and D), suggesting an important role for 
CD11c+ cells. To determine whether CD11c+ cell–produced IL-18 
is essential for rapid IFN-γ secretion, mixed Il18–/–/CD11cDTR 
chimeras were compared with WT/CD11cDTR chimeras. In this 
system, IL-18–producing CD11c+ cells can be selectively depleted 
without affecting other IL-18–producing hematopoietic cell types. 
DTX-treated Il18–/–/CD11cDTR chimeras did not produce IL-18 or 
IFN-γ upon Mtb challenge, whereas WT/CD11cDTR chimeras did, 
revealing a critical role for CD11c+ cells as the source of IL-18 (Fig-
ure 5, E–G, and Supplemental Figure 4, E and F).
To determine whether CD11c+ cell types also take up Mtb 
within 24 hours, we used Mtb-GFP and tracked bacterial uptake 
by different immune cell subsets. Splenic CD11c+ cell types com-
prised half of all GFP-expressing Mtb after i.v. injection (Figure 
5H), and lung CD11c+ cells were the second-most infected cell type 
after i.t. Mtb-GFP administration (Supplemental Figure 5I). In the 
spleen, almost all CD11c+ cells are DCs. A more detailed charac-
terization of splenic DC subsets revealed a preferential uptake of 
Mtb-GFP by CD8+ and CD4–CD8– (DN) DC subsets (Figure 5I). 
These results not only demonstrate a crucial role for CD11c+ cells 
in the secretion of IL-18 after Mtb exposure, but also suggest that 
CD8+ and DN DC subsets should be exploited as potential targets 
to induce IL-18–dependent immune defense mechanisms.
IL-18 is required for early noncognate protection against Mtb- 
induced disease. To address whether the early defense against TB 
mediated by noncognate sources of IFN-γ (Figure 1) also depends 
on IL-18, Rag1–/– mice (NK cells) and Rag2–/– Il2rg–/– mice that had 
received OT-ITg cells 4 weeks earlier (noncognate memory CD8+ 
T cells) were infected with Mtb and subsequently treated with neu-
Figure 4. IL-18–dependent IFN-γ secretion requires canonical NLRP3 signaling and is independent of surface receptor engagement. Percentage of viable 
lung IFN-γ+ cells among total CD3–NK1.1+ (A and D) and CD3+CD8+ (B and E) cells and serum IL-18 concentrations (C and F) 24 hours after i.v. injection of 1 × 108  
CFU Mtb H37Rv into different strains of mice lacking either key components of cytosolic PRR pathways (A–C) or key surface receptors involved in Mtb recog-
nition and innate immune responses (D–F), or into B6 mice treated with different Abs (G and H). Results are presented as pooled data (mean ± SEM) (A and 
B) or as individual data points (C–H) of 5 to 16 (A–C), 7 to 10 (D–F), or 6 (G and H) mice per group from at least 2 pooled, independent experiments. *P < 0.05, 
**P < 0.01 and ***P < 0.001, relative to B6 controls (A–F) by 1-way ANOVA.
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tralizing anti–IL-18 or control Ab. In both settings, anti–IL-18 treat-
ment reversed the protective phenotype; mean survival in Rag1–/– 
mice was reduced from 49 days for control mice to 39 days for 
mice treated with anti–IL-18 (Figure 6A). Very similar results were 
obtained with Rag2–/– Il2rg–/– mice harboring memory OT-ITg cells. 
Whereas all Rag2–/–  Il2rg–/– mice treated with anti–IL-18 succumbed 
to infection by day 35, animals treated with control IgG showed no 
signs of disease by this time point, and 50% of mice survived past 
day 60 (Figure 7A). Furthermore, anti–IL-18 treatment significantly 
increased bacterial numbers in spleen and lung (Figure 6, B and C, 
and Figure 7, B and C), significantly exacerbated lung pathology, 
with large clusters of cell infiltrates (Figure 6, D and E, and Fig-
ure 7, D and E), and elevated the abundance of proinflammatory 
cytokines such as TNF-α, IL-6, and IL-1β (Figure 6F and Figure 7F). 
Additionally, despite an increase in bacterial numbers and cell infil-
tration, anti–IL-18 administration reduced iNOS expression in lung 
tissue compared with that detected in untreated or control IgG–
treated animals (Figure 6D and Figure 7D), indicating that anti–
IL-18 treatment had a detrimental impact on effector mechanisms 
downstream of IFN-γ. Taken together, these results substantiate 
that IL-18 drives early IFN-γ–mediated defense against TB by NK 
cells and Mtb-unrelated memory CD8+ T cells.
ESAT-6–dependent cytosolic contact improves vaccine-induced 
protection. To finally investigate whether ESAT-6–mediated 
cytosolic contact and subsequent IL-18–mediated IFN-γ secre-
tion could potentially be exploited for improved TB intervention 
strategies, we performed exploratory BCG vaccination experi-
ments. It was recently demonstrated that rapid, cytokine-driven 
IFN-γ secretion by memory CD8+ T cells instructs innate cells to 
become more potent effector cells, thereby significantly affect-
ing the magnitude of the secondary recall response after pri-
mary L. monocytogenes infection (31). Given that in our model, 
i.v. exposure of mice with RD1-containing mycobacteria gen-
erated the strongest, most ubiquitous and rapid systemic IFN-γ 
response (Figures 2 and 3), B6 mice were vaccinated via the i.v. 
route with a high dose of BCG, BCG::RD1, or BCG::RD1 ESAT-6 
Δ92-95. After 60 days, mice were aerosol challenged with Mtb 
H37Rv (Figure 8A). Only i.v. vaccination with BCG::RD1, but not 
BCG::RD1 ESAT-6 Δ92-95, significantly improved protection 
against the Mtb challenge compared with vaccination with BCG 
(Figure 8, B and C). Considering that all vaccine strains induced 
a similar cytokine milieu after Mtb challenge (Figure 8C) and that 
BCG::RD1 ESAT-6 Δ92-95 still contains all of the key protective 
ESAT-6 T cell epitopes (57), these findings strongly suggest that 
ESAT-6–mediated cytosolic translocation and subsequent innate 
IFN-γ secretion positively impact TB vaccine efficacy. Further 
work will have to clarify to what extent these findings depend on 
the ESAT-6–mediated IL-18 secretion described in this study and 
Figure 5. A BM-derived CD11c+ cell population is required for IL-18 secretion in response to Mtb. (A–G) Percentage of IFN-γ+ cells among total lung CD3–NK1.1+ 
(A, C, and E) and CD3+CD8+ (B, D, and F) cells and serum IL-18 levels (G) of straight WT or Il18–/– (A and B) and CD11cDTR BM chimeras (C and D) as well as DTX- 
and PBS-treated CD11cDTR mixed BM chimeras (E and F) 24 hours after injection of 1 × 108 CFU Mtb H37Rv. (H) Percentage of GFP+ cells among total viable 
splenocytes 24 hours after i.v. or i.t. injection of 1 × 108 CFU Mtb H37Rv or Mtb H37Rv–GFP into naive B6 mice. (I) Uptake of Mtb H37Rv–GFP by individual 
splenic DC subsets (CD11c+MHC-II+CD4+, CD11c+MHC-II+CD8+, or CD11c+MHC-II+CD4–CD8–) 24 hours after i.v. or i.t. delivery of 1 × 108 CFU. Results are presented as 
individual data points (A–G) or as pooled data (mean ± SEM) and representative FACS plots (H and I) of 8 to 10 (A–G) or 4 to 6 (H and I) mice per group from 2 
(H and I) or 3 (A–G) pooled, independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, by 1-way ANOVA. Mtb-GFP, Mtb H37Rv–GFP; PI, propidium iodide.
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The efficacy of subunit protein vaccines is dependent on the 
right choice of adjuvants (59), which activate appropriate PRRs 
such as TLRs (60, 61). In contrast, live attenuated vaccines rarely 
require adjuvants, as some of the ligands involved in adjuvan-
ticity are already contained in the live vaccine (62). With a more 
detailed understanding of ligand-PRR interactions and the result-
ing immune responses of vaccine strains, a more targeted design 
of recombinant live vaccines becomes feasible. In line with this, 
we have recently elucidated that activation of the AIM2 inflam-
masome contributes to the superior protection afforded by a 
recombinant BCG strain compared with that seen with conven-
tional BCG vaccination (63). Here, we show that rapid IL-18 secre-
tion that significantly contributes to early protective immunity 
against TB depends on ESAT-6–mediated NLRP3, but not AIM2, 
inflammasome activation. Incorporating NLRP3 inflammasome–
based mechanisms that lead to innate IFN-γ production by non-
specific memory CD8+ T cells and NK cells should, therefore, also 
be taken into consideration for future TB vaccine improvement.
Our study also shows that NLRP3 activation in response to 
Mtb depends on RD1-mediated and ESAT-6–dependent cytoso-
lic contact, a feature that is incorporated in the recombinant BCG 
strain BCG::RD1 (43). However, because of increased virulence 
in immunocompromised hosts as well as prolonged persistence 
in fully immune-competent hosts, BCG::RD1 has been deemed 
whether ESAT-6–mediated cytosolic translocation can be uncou-
pled from the detrimental aspects of RD1.
Discussion
Our study provides compelling evidence for a protective role 
of noncognate lymphocytic sources of IFN-γ in TB. We demon-
strate that memory CD8+ T cells with an unrelated specificity as 
well as NK cells protect against acute TB via IL-18–dependent 
IFN-γ secretion. Furthermore, we provide a comprehensive 
mechanistic framework for how IL-18–dependent innate IFN-γ 
is produced in response to Mtb, including a crucial role for bacte-
rial viability, ESAT-6–dependent cytosolic contact, and NLRP3 
activation (Figure 9). The observations that both memory CD8+ 
T cells and NK cells can act as the sole source of host-protec-
tive IFN-γ during Mtb infection highlight the redundancy in the 
source of IFN-γ during early Mtb infection and reveal a previously 
unappreciated level of functional interchangeability between 
IL-12 (33) and IL-18 during Mtb infection. Considering that (a) 
IFN-γ can orchestrate host innate immune responses and has 
an impact on the magnitude of recall responses (31) and that (b) 
IL-18 has beneficial effects on antigen-specific T cell responses 
(58), induction of host-pathogen interactions that lead to rapid, 
IL-18–dependent IFN-γ secretion should be a crucial feature of 
improved TB intervention strategies.
Figure 6. Early control of Mtb infection by NK cells depends on IL-18. Rag1–/– mice were infected with 200 CFU Mtb H37Rv via the aerosol route and 
treated weekly with either anti–IL-18 Ab or control IgG or were left untreated. As an additional control, naive Rag1–/– mice were treated with anti–IL-18 Ab. 
Long-term survival (A), CFU in lung and spleen (B and C), a cytokine profile (F), as well as cell infiltrates (D and E) and iNOS expression in lung tissue (D) 
were assessed 34 days p.i. Results are presented as individual data points (B, C, and E), pooled data (mean ± SEM) (F), and representative images (D) of 
6 (A) or 5 (B–F) mice per group from 2 pooled independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001, by log-rank (Mantel-Cox) test (A), 1-way 
ANOVA (B, C, and E), and 1-way ANOVA for each cytokine (F). Original magnification, ×25 (Giemsa), ×50 (TB-Fluor), ×100 (iNOS). G-CSF, granulocyte-CSF; 
GM-CSF, granulocyte macrophage–CSF.
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rapid NLRC4 inflammasome activation occurred predominantly 
in CD8+ DCs (21) and, additionally, emphasizes the substantial 
differences between BM-derived myeloid cell populations and 
bona fide DCs found in vivo (67). Human equivalents of mouse 
CD8+ DCs have been identified as XCR1+CD141+ cells (68), and 
there is increasing evidence that most mouse DC subsets have a 
human phenotypic and functional equivalent (69). In addition, 
studies of other pathogens have identified murine Ly6C+CCR2+ 
inflammatory monocytes as sensor cells for L. monocytogenes 
infection (23) and subcapsular sinus macrophages as sensor cells 
for P. aeruginosa infection (22), resulting in the release of IL-18 and 
the subsequent production of IFN-γ by innate cell types. These 
discrepancies highlight the need to investigate the mechanistic 
framework underlying noncognate IFN-γ production indepen-
dently for different pathogens. In particular, identifying which 
antigen-presenting cell (APC) subset is most efficient at sensing 
a specific class of pathogens in vivo remains critical. Because of 
the diverse expression of different internalization receptors and 
the abundance of inflammasome components, various myeloid 
cells are endowed with unique abilities to interact with Mtb. In this 
context, characterization of the myeloid cell population, which 
produces IL-18 in an NLRP3-dependent manner (CD8+ and DN 
DCs capable of cross-presentation), will foster innovative strat-
egies for ESAT-6–mediated NLRP3 activation. Our study pro-
vides a complete mechanistic framework for noncognate in vivo 
an unsuitable human vaccine candidate, despite increased sys-
temic protection over BCG against Mtb challenge (43, 64). To 
combine enhanced protection with decreased virulence, a panel 
of BCG::RD1 strains with distinct aa changes in the esxA gene 
were recently evaluated as vaccine candidates (65). Some of these 
strains showed high protective capacity with low virulence in both 
mouse and guinea pig models (65). These observations suggest 
that a fine-tuned balance needs to be found between inducing pro-
tective immune responses and limiting virulence. While a com-
plete loss of biological activity of ESAT-6 may lead to decreased 
virulence, but not to improved vaccine-induced protection (44, 47, 
64, 66), targeted aa substitutions that only affect the stability of 
ESAT-6 may combine both effects (65, 66). Overall, these results 
indicate that a detailed understanding of immune responses stim-
ulated by different vaccine candidates in a spatiotemporal frame-
work may be used to design a next-generation live, recombinant 
vaccine against TB that combines beneficial features of several of 
the current vaccine candidates.
While recombinant ESAT-6 is sufficient to activate the NLRP3 
inflammasome in macrophages in vitro (55), our study suggests 
that in vivo cytosolic NLRP3 activation depends on active ESAT-6 
secretion by viable Mtb and the immune architecture. In particu-
lar, CD8+ and DN CD11c+ DCs appear to be required for rapid Mtb 
uptake and subsequent IL-18 secretion in the spleen. This is in line 
with observations made during Salmonella infections, in which 
Figure 7. Early control of Mtb infection by noncognate memory CD8+ T cells depends on IL-18. Rag2–/– Il2rg–/– mice that had received OT-ITg cells 4 weeks 
earlier were infected with 200 CFU Mtb H37Rv via the aerosol route and treated weekly with either anti–IL-18 Ab or control IgG. Long-term survival (A), 
CFU in lung and spleen (B and C), a cytokine profile (F), as well as cell infiltrates (D and E) and iNOS expression in lung tissue (D) were assessed 27 days 
p.i. Results are presented as individual data points (B, C, and E), pooled data (mean ± SEM) (F), and representative images (D) of 12 (A) or 7 (B–F) mice per 
group from 2 pooled, independent experiments. *P < 0.05 and **P < 0.01 by log-rank (Mantel-Cox) test (A), unpaired, 2-tailed Student’s t test (B, C, and 
E), and 1-way ANOVA for each cytokine (F). Original magnification, ×50 (Giemsa), ×100 (TB-Fluor), ×200 (iNOS).
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Therefore, determining which human APC subset in different tis-
sues is the most efficient one for sensing ESAT-6 might enable the 
development of improved strategies aimed at the targeted delivery 
of TB vaccines to a particular APC subset (73, 74) and lead to opti-
mal and localized IL-18–mediated IFN-γ secretion.
Another critical question arises from our study: how does 
ESAT-6 activate NLRP3 in vivo? Restriction of phagosomal acid-
ification was shown to be a crucial prerequisite for ESX-1–depen-
dent phagosomal rupture and rapid cytosolic contact in vivo (71). 
Although ESAT-6 is known for its membrane-damaging capa-
bilities, direct activation of the NLRP3 inflammasome through 
ESAT-6–mediated translocation of Mtb components into the 
cytosol cannot be excluded. Assembly of NLRP3 inflammasomes 
requires cytosolic sensing of danger signals or activation through 
specific surface receptors (26). At least 4 models for NLRP3 activa-
tion exist: the lysosomal rupture model; the pore formation model; 
the ROS model; and the K+ efflux model (75). To date, these models 
have not been experimentally proven or disproven. Furthermore, 
increasing evidence suggests that direct access of the NLRP3-acti-
vating agent to the cytosol may not be required, because “tickling” 
of the DC surface with alum also appears to initiate NLR activation 
(76). These observations suggest a possible role for interactions 
with surface or endosomal receptors and warrant further investi-
gation into the possibility of cross-linking antigens to specific lig-
ands for surface receptors of distinct DC subsets such as XCR1, 
SIGN, DEC205, or CLEC9A. Further research will be required to 
determine the processes involved in the transfer of Mtb pathogen–
associated molecular patterns (PAMPs) from the phagosome into 
the cytosol and to what extent soluble N-ethylmaleimide–sensi-
protection against an intracellular pathogen. We have identified 
the activating mycobacterial factor, the sensing APC subset, and 
the cytosolic NLR molecule. Although cytosolic egress (70) and 
ESAT-6–dependent phagosomal destabilization (71) have been 
described for macrophages and DCs, this is the first study to our 
knowledge to link inflammasome activation and IL-18 release in 
the context of adaptive immunity in TB. We consider the identi-
fication of ESAT-6–dependent activation of NLRP3 in a bona fide 
DC subset in vivo a significant step forward in the development of 
innovative T cell therapies.
In line with these observations, our data emphasize that the 
route of mycobacterial exposure has a profound impact on IL-18–
dependent IFN-γ production as well as on protection against 
Mtb challenge after vaccination. Whereas i.v. infection with Mtb 
resulted in up to 6 ng/ml IL-18, i.t. administration only yielded 
up to 1 ng/ml IL-18, confirming that IL-18 levels directly correlate 
with the amount of IFN-γ being produced by memory CD8+ T cells 
and NK cells (21). There are several factors that could explain why 
i.t. infection induces lower IL-18 secretion: (a) the lower number 
of DCs in the lung compared with numbers in the spleen; (b) the 
slower access of Mtb to the bloodstream and therefore to distant 
CD11c+ cells; and (c) the organ-specific differences in regula-
tory mechanisms. Although i.v. administration of a vaccine may 
be unpopular, it is interesting to note that malaria vaccine trials 
using irradiated sporozoites only showed protection after i.v. vac-
cination (72). Strategic location of APC subsets within the tissue 
as well as proximity to IL-18–responsive cell types appear to be 
crucial features, dictating not only the effectiveness of the early 
immune response but also of the secondary recall of immunity. 
Figure 8. Cytosolic contact of ESAT-6 improves vaccine-induced protection. (A) B6 mice were vaccinated i.v. with 1 × 107 CFU BCG, BCG::RD1, or BCG::RD1 
ESAT-6 Δ92-95. Sixty days later, mice were aerosol infected with 200 CFU Mtb H37Rv. Twenty-eight days p.i., mice were sacrificed, and CFU in spleen and 
lung (B) as well as serum cytokines (C) were assessed. Results are presented as pooled data (mean ± SEM) of 6 mice per group from 2 pooled, independent 
experiments. **P < 0.01 and ***P < 0.001, by 1-way ANOVA (B).
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IL-15–IL-15RαFc complexes have been shown to boost NK cell and 
memory CD8+ T cell numbers and enhance their killing capacity 
(82). In certain instances, the therapeutic potential of IL-15 and/
or IL-2 transpresentation may prove to be a very effective way of 
activating and boosting noncognate cell activity, particularly in 
the absence of CD4+ T cells.
In summary, our findings: (a) demonstrate a role for Mtb- 
unrelated immune cells in IFN-γ–mediated protection against TB; 
(b) delineate the mechanistic framework for the production of 
IL-18–dependent production of IFN-γ by such noncognate cells; 
and (c) provide initial exploratory results suggesting that IL-18–
responsive cell types are potential targets for preventive interven-
tion. Considering that rapid, IL-18–dependent IFN-γ responses 
are not evoked by current first- and second-generation TB vaccine 
candidates, we believe that this has critical implications for the 
future design of vaccines and host-directed therapy in TB.
Methods
Mice. C57BL/6J and C57BL/6N mice were purchased from Charles 
River Laboratories. The following KO and Tg mouse strains were used: 
Il18–/–, Il1b–/–, Tlr2–/–/Tlr4–/–, Ifngr–/–, Ifnabr–/–, and Myd88–/– (provided 
by B. Raupach, Max Planck Institute for Infection Biology [MPIIB], 
Berlin, Germany); Nlrp3–/– (provided by J. Tschopp, University of Lau-
sanne, Lausanne, Switzerland); caspase-1–/–, caspase-11–/–, caspase-1–/– 
and caspase-11–/–, and Asc–/– (provided by V. Dixit, Genentech, San 
Francisco, California, USA); 129S2/SvPas (provided by R. Kemler, 
Max Planck Institute for Immunobiology and Epigenetics [MPI-IE], 
Freiburg, Germany); CD45.1+, Rag1–/–, and Rag2–/– Il2rg-/– (provided by 
F. Melchers, MPIIB, Berlin, Germany); OT-ITg (from The Jackson Lab-
oratory); Sting–/– (provided by Lei Jin, Albany Medical College, Albany, 
New York, USA); Aim2–/– (83) (provided by V. Hornung, University of 
Bonn, Bonn, Germany); CD11cDTR (provided by H.D. Chang, Ger-
man Rheumatism Research Center [DRFZ], Berlin, Germany); and 
Ifng–/– and P14 LCMVgp33-41 TCRtg (provided by M. Löhning, DRFZ, 
Berlin, Germany ). All mice were bred and maintained at the MPIIB, 
the Research Institutes for Experimental Medicine (FEM) Charité, 
and the DRFZ (all located in Berlin, Germany). For infection exper-
iments, all mice were sex and age matched and kept in our biosafety 
level facility (BSL 3) under specific pathogen–free (SPF) conditions.
Bacterial strains and infection of mice. All Mtb and BCG strains were 
grown in Middlebrook 7H9 broth (BD Biosciences) supplemented with 
0.2% glycerol, 0.05% Tween-80, and 10% albumin dextrose catalase 
(ADC) enrichment (BD Biosciences) and appropriate antibiotics if 
necessary. The Mtb strain H37Rv ΔESAT-6 was provided by D. Sher-
man (University of Washington, Seattle, Washington, USA). Recombi-
nant BCG::RD1 strains and derivatives were constructed as described 
previously (65). Stm SL1344 was grown overnight at 37°C with shaking 
in Luria Bertani broth. Midlogarithmic cultures of all strains were har-
vested, washed in PBS, and stored at –80°C. For all short-term assays, 
tive factor attachment receptor (SNARE) proteins such as Sec22B 
and Sec61 (77, 78) are involved in such transfers.
On the other hand, NLRP3 activation also needs to be con-
trolled tightly, because hyper-activation or gain-of-function 
mutations can result in excessive inflammation, autoinflamma-
tory syndromes, or metabolic disorders (79). Detrimental aspects 
of NLRP3 activation are often linked to excessive production of 
IL-1β. Whether IL-18 secretion can be uncoupled from IL-1β pro-
duction is not entirely clear. IL-1β secretion requires a priming sig-
nal that leads to transcriptional activation of pro–IL-1β synthesis 
(26), whereas pro–IL-18 is considered to be preformed. Although 
our findings demonstrate that ESAT-6–mediated IL-18 secretion 
does not depend on TLR- or IFN-dependent priming signals, it 
appears unlikely that a strategy aimed at activating NLRP3 with-
out prior activation of priming signaling pathways can be achieved 
using a live whole-cell vaccine. Furthermore, it may be important 
to consider existing mutations in inflammasome pathways that 
may compromise the effectiveness of a vaccine. The effect of 
NLRP3 mutations on autoinflammatory and other diseases (80, 
81) is well documented. These considerations will be critical in 
order to maximize the potential of personalized medicine targeted 
at patient cohorts for which current intervention strategies might 
be ineffective or fatal. For example, in order to potentially harness 
the host-directed therapeutic effects from IL-18–dependent IFN -γ 
production, it could also be beneficial to both activate IL-18–
responsive cell types and boost cell numbers. IL-2–anti–IL-2 and 
Figure 9. ESAT-6–dependent cytosolic pattern recognition drives non-
cognate TB control in vivo. Model depicting the mechanistic framework 
underlying mycobacterial growth control by noncognate sources of IFN-γ. 
Cytosolic translocation of ESAT-6 activates the NLRP3 inflammasome by 
a yet-to-be-defined mechanism within CD11c+ cells. Subsequent secretion 
of IL-18 drives the secretion of host-protective IFN-γ by Mtb-unrelated 
memory CD8+ T cells and NK cells.
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β-TCR (clone H57-597); γδ-TCR (clone GL3); CD62L (clone MEL-14); 
CD44 (clone 1M7); CD90.1 (clone 30-H12); CD11b (clone M1/70); 
CD11c (clone HL3); MHC II (clone AF6-120.1); CD103 (clone 2E7); 
Ly6G (clone 1A8); F4/80 (clone BM8); TCR Vβ Repertoire Kit (Beck-
man Coulter); or IFN-γ detection Ab (Miltenyi Biotec), as described 
elsewhere (21). After washing the cells, samples were analyzed using a 
FACSCanto II or an LSR II flow cytometer (both from BD Biosciences). 
Propidium iodide (2 μg/ml) was added to exclude dead cells.
Histology and immunofluorescence. Lung lobes were collected 
aseptically, fixed overnight with 4% w/v paraformaldehyde, and 
embedded in paraffin. Tissues were cut at 2-μm thickness and stained 
with Giemsa, TB Fluor (Merck), or anti-iNOS Ab (Thermo Scientific) 
according to standard protocols described elsewhere (28).
Isolation, enrichment, and in vitro expansion of NK cells. NK cells 
were negatively isolated from the spleens and LNs of donor mice 
using an NK cell enrichment kit and MACS Cell Separation Tech-
nology (Miltenyi Biotec) according to the manufacturer’s instruc-
tions. Isolated and purified NK cells were cultured with recombinant 
human IL-2 (Peprotech) as described previously (85). The purity of 
cells after culture was determined by flow cytometry, and 1 × 106 NK 
cells were adoptively transferred i.v. on days 5 and 6 after culture into 
naive Rag–/– Il2rg–/– mice.
Multiplex and ELISA. Blood for serum analysis was taken postmor-
tem from the aorta abdominalis, collected in serum separator tubes 
(BD), and left for 30 minutes at room temperature, followed by cen-
trifugation at 12,000 ×g for 3 minutes. Sera were stored at –20°C until 
analysis. Measurements were performed using multiplex bead–based 
immunoassay kits (Bio-Rad) or ELISA (MBL) according to the man-
ufacturer’s instructions. Samples were acquired on a Bio-Rad instru-
ment or a SpectraMax ELISA Reader (Molecular Devices).
Generation and transfer of Tg memory CD8+ T cells. Tg CD62Lhi mem-
ory CD8+ T cells were prepared as described previously (36). In brief, 
splenocytes from Tg OT-I or P14 mice were incubated with SIINFEKL or 
KAVYNFATC peptide–coated irradiated syngeneic splenocytes, respec-
tively, and cultured for 4 days at 37°C. The activation of Tg cells was 
checked routinely by staining cells with anti-CD8α (clone 53-6.7; BD); 
anti-Vα2 (clone B20.1; BD); and anti-CD25 (clone PC61.5; BD) and ana-
lyzing by flow cytometry. Activated OT-ITg or P14Tg cells (1 × 107) were 
adoptively transferred into naive Rag2–/– Il2rg–/–, Ifngr–/–, or B6 recipients. 
Mice were aerosol infected with Mtb H37Rv 4 to 6 weeks later.
Abs. For cytokine neutralization, mAbs against IL-18 and IFN-γ 
were produced and purified in-house from hybridomas using standard 
techniques (86). Neutralizing mouse IL-15 Ab was purchased from 
R&D Systems. A total of 200 μg anti–IL-18 (clone SK113AE4; provided 
by I. Förster, University of Bonn, Bonn, Germany); anti–IFN-γ (clone 
XMG1.2); anti–IL-15 (catalog AF447; R&D Systems); or control rat IgG 
was injected i.p. weekly in a volume of 200 μl.
Statistics. Flow cytometric data were analyzed using FlowJo soft-
ware, and statistical analysis was performed using GraphPad Prism, 
version 5.04 (GraphPad Software). One-way ANOVA was followed by 
Bonferroni’s multiple comparisons test for parametric samples, and 
unpaired, 2-tailed Student’s t tests were used. A P value of less than 
0.05 was considered significant.
Study approval. All animal experiments were conducted according 
to German animal protection laws and approved by the State Office 
for Health and Social Affairs Berlin (Landesamt für Gesundheit und 
Soziales Berlin; LAGeSo, T0087/13, G0031/13).
mice were infected i.v., i.t., s.c., or i.d. with different doses of bacteria 
(as indicated in the figure legends) in a volume of 50 to 200 μl. For 
aerosol infection, animals were exposed to a dose of approximately 
200 CFU Mtb/mouse, using a Glas-Col inhalation exposure system. 
At designated time points, serial dilutions of tissue homogenates were 
plated onto Middlebrook 7H11 agar supplemented with 10% Middle-
brook oleic albumin dextrose catalase (OADC) Enrichment (BD Bio-
sciences), ampicillin (25 μg/ml), and appropriate additional antibiot-
ics if necessary. CFU were determined after 3 to 4 weeks of incubation 
at 37°C. For survival experiments, mice were sacrificed when a mori-
bund state was reached. Death was never used as an endpoint.
Vaccinations. C57BL/6 mice were vaccinated with BCG, 
BCG::RD1, or BCG::RD1 ESAT-6 Δ92-95 i.v. in the lateral tail vein 
with 1 × 107 CFU in a volume of 200 μl. Sixty days after vaccination, 
mice were challenged with 200 CFU Mtb H37Rv via the aerosol route. 
At designated time points, spleen and lung were removed aseptically, 
homogenized in PBS with 0.05% Tween-80, and plated in serial dilu-
tions onto 7H11 agar containing 2-thiophenecarboxylic acid hydride 
(TCH) (84) to prevent BCG growth.
Heat inactivation of bacteria. For heat inactivation, bacteria were 
grown as described above, enumerated, and washed twice with PBS 
before incubation at 65°C in a water bath for 1 hour. Effective killing 
was verified by plating heat-killed bacteria onto appropriate agar plates.
Isolation of lung leukocytes. Lungs were perfused with PBS, 
extracted, mechanically disrupted, and digested via incubation for 
30 minutes with RPMI 1640 medium supplemented with glutamine, 
Na-pyruvate, 2-ME, penicillin, streptomycin, 10% heat-inactivated 
FCS, collagenase D (Roche), and collagenase type VIII (Sigma- 
Aldrich). Subsequently, rbc-depleted, single-cell suspensions were 
prepared as described elsewhere.
BM chimeric mice and selective depletion of DCs. BM chimeric 
mice were generated as described previously (21). Briefly, C57BL/6 
mice were irradiated with 9 Gy and reconstituted with 5 × 106 T cell–
depleted BM cells from Il18–/–, Tg CD11cDTR, or CD45.1 mice. For 
mixed BM chimeras, irradiated mice were reconstituted with a 1:1 
mixture of BM from different mice. Chimeric mice were maintained 
for 6 weeks on drinking water containing enrofloxacin antibiotic (125 
mg/l) and allowed to reconstitute for at least 8 weeks. Depletion of 
CD11c+ cells was achieved by injecting CD11cDTR chimeric mice i.p. 
twice with 100 ng DTX 3 days and 1 day before the start of experi-
ments. Effectiveness of depletion was checked by flow cytometry.
Assessment of ex vivo IFN-γ secretion. Ex vivo IFN-γ secretion by dis-
tinct lymphocyte subsets was assessed as described previously (21). 
Briefly, mice were injected i.v., i.t., s.c., or i.d. with different doses of 
bacteria (as described in the figure legends), heat-inactivated bacte-
ria, or purified ligands (BEI Resources, National Institute of Allergy 
and Infectious Diseases [NIAID], NIH). At different time points (as 
described in the figure legends) after injection of bacteria, organs were 
aseptically removed, single-cell suspensions were prepared, and rbc 
were lysed. Cells (1 × 106) were stained with the Mouse IFN-γ Secretion 
Assay Detection Kit (Miltenyi Biotec) according to the manufacturer’s 
instructions, and IFN-γ secretion was analyzed by flow cytometry.
Flow cytometry. To assess the expression of surface antigens and 
IFN-γ secretion, viable, rbc-depleted single-cell suspensions were 
stained with mAbs (all from BD Pharmingen) against CD4 (clone 
GK1.5); CD8α (clone 53-6.7); CD3 (clone 145-2C11); NK1.1 (clone 
PK136); CD45.1 (clone A20); CD45.2 (clone 104); CD49b (clone DX5); 
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